Amphiphilic poly(amino acid) based micelles applied to drug delivery The in vitro and in vivo challenges and the corresponding potential strategies

Purpose: Amphiphilic poly(amino acid)-based micelles are attractive for systemic drug delivery because they are biodegradable, biocompatible, have functional side groups, can load diverse drugs, and can exploit the EPR effect. However, low cargo capacity and poor stability in blood remain major barriers to clinical translation. This review summarizes the chemistry, drug-loading forces, in vitro/in vivo challenges, and strategies to improve loading and stability.

Hypothesis: This is a review article, so it does not test a single formal hypothesis. Its central premise is that drug loading capacity is governed by the interaction forces between drug and polymer, while in vivo stability is determined by thermodynamic/kinetic stability and resistance to blood dilution, plasma protein adsorption, and ionic strength. Rational copolymer design and stabilization strategies can overcome these barriers.

Aims: Describe typical structures, synthesis, and characteristics of amphiphilic poly(amino acid) copolymers. - Summarize strategies to increase drug loading capacity via non-covalent interactions and covalent drug–polymer conjugates. - Outline drug release profiles and in vivo pharmacokinetics of drug-loaded micelles. - Analyze causes of in vivo instability: blood dilution, plasma protein interactions, and ionic strength. - Review stabilization strategies: cross-linking, layer-by-layer coating, hybrid/mixed micelles, and α-helix bundles. - Highlight preclinical and clinical development status of representative micellar formulations.

Delivery system: Micelle type: Core–shell polymeric micelles from amphiphilic block or graft copolymers. - Poly(amino acid) building blocks: Poly(L-glutamic acid) (PGlu), poly(L-aspartic acid) (PAsp), poly(L-lysine) (PLL), γ-poly(glutamic acid) (γ-PGA), ε-polylysine (ε-PLL), and analogues. - Hydrophilic shell: PEG, PEOz, etc.; hydrophobic core: PLLA, PLGA, PCL, polyphenylalanine (PPhe), polyleucine, cholesterol, aliphatic/aromatic grafts. - Payloads: Hydrophobic drugs (PTX, DOX, ATPR, plitidepsin, curcuminoids), cationic drugs (DOX·HCl, amphotericin B), proteins/peptides (G-CSF, lysozyme, OVA), nucleic acids (pDNA, siRNA, ODN), and platinum drugs (CDDP, oxaliplatin, DACHPt). - Loading mechanisms: Hydrophobic interaction, electrostatic interaction, polymer–metal coordination, and covalent conjugation (amide/ester bonds, pH-sensitive hydrazone bonds, etc.). - Targeting: Passive EPR-based tumor accumulation is emphasized; active targeting is not the main focus.

Approach: Review of the literature, covering in vitro and in vivo preclinical studies and clinical trials. Model systems include cancer cell lines (MCF-7, A549, HepG2, colon 26, etc.), mouse xenografts, and rats. Clinical-stage formulations discussed include NK911, NK105, NC-6004, and NK012. No new primary experiments are reported.

Key methods: Synthesis: Ring-opening polymerization of N-carboxyanhydrides (NCAs), deprotection, grafting, and block copolymerization. - Characterization: Circular dichroism for α-helix/random coil conformation; DLS/light transmittance for pH-responsive size changes; SEC, DLS/SLS, FRET, and ultracentrifugation for serum stability and protein interactions. - Drug loading: Drug loading (DL) and entrapment efficiency (EE); release profiles at pH 7.4 vs acidic pH. - In vivo: Pharmacokinetics (AUC, Cmax, t1/2, MRT, CL), biodistribution, and antitumor efficacy.

Key results: Drug loading examples: PEG-b-PAsp-DOX conjugate DL 17%, 15–60 nm; PEG-b-PGlu-CDDP coordination DL 30%, ~30–40 nm; NK105 PTX DL 23%, ~85 nm; PEG-b-PGlu CPT-11 conjugate DL 20%, 20 nm; mPEG-b-PGlu DOX electrostatic DL 30%, ~90 nm; mPEG-b-PGlu G-CSF EE ~100%, 60–70 nm; PEO2-b-PAsp AmB DL 47%, EE 97%, 108 nm. - High-loading examples: DOX-conjugated PEG-PAsp with additional π–π physical entrapment reached DL 37%; Na-micelles loaded DOX at DL 56.8% vs 1.1% for Bz-micelles. - Pharmacokinetics: ATPR micelles showed AUC0–∞ 2.23× and MRT 1.67× higher, and CL 2.25× lower than ATPR solution. DOX-loaded mPEG-b-PGlu micelles showed t1/2 1.4×, MRT0–t 2.2×, and AUC0–t 2.8× higher than free DOX. NK911 showed Cmax 36.4× and AUC0–24h 28.9× higher than free DOX. NC-6004 Phase I showed total platinum Cmax/AUC 11× higher than cisplatin, with 88% present as intact micelles. - Stability challenges: Blood dilution can require 6–30 mg polymer dose to maintain micelles; CMC is often 1–5 mg/L. Plasma proteins (albumin, IgG, fibrinogen) can cause premature release, aggregation, or clearance. Physiological salt (0.15 M NaCl) can dissociate polyion complex micelles; e.g., PEG-PAsp/lysozyme micelles lost ~90% light scattering at physiological salt. - Stabilization: Cross-linked micelles remained stable in 8 M urea. α-Helix bundle micelles maintained structure in chloride-containing medium and showed lower liver/spleen accumulation than racemic micelles.

Interpretation: Amphiphilic poly(amino acid) micelles can load diverse drugs through multiple interaction forces and achieve high DL with pH-responsive release. However, a single driving force is often insufficient for in vivo stability. Multiple interactions, cross-linking, layer-by-layer coating, hybrid/mixed micelles, and α-helix bundles are needed. Drug–polymer conjugates generally show better stability and longer circulation. Maintaining robust drug–polymer interaction and intact micellar structure in blood is a prerequisite for targeted antitumor efficacy and reduced toxicity.

Limitations: This is a review, not a primary study; no new experimental data or meta-analysis. - Many stabilization strategies remain preclinical; clinical data are limited to a few formulations. - Studies use heterogeneous methods and endpoints, making direct comparisons difficult. - Long-term safety, immunogenicity, scalable manufacturing, and regulatory issues are not deeply addressed. - Active targeting and intracellular trafficking beyond pH-responsive release are less covered.